Biomarker discovery identifies multiple candidates which need validating before being taken into clinical studies. When antibodies are not readily available selective reaction monitoring (SRM) offers a rapid, cost effective way to generate validated multiplex assays that are optimized to specifically monitor your candidate biomarkers at a sensitivity suitable for your sample type. PS Biomarker Services™ Assay Development module produces validated SRM assays using any of the established methods and our expert scientists will help you select the optimum strategy to validate your panel of candidates.
Assay Development Technology Selector
I want to validate candidate biomarkers from TMT® Discovery experiments
I want to validate candidate biomarkers from other discovery experiments
I want to validate my candidate biomarkers but have limited time and / or budget
I want to validate candidate biomarkers that do not have commercially available antibodies
I want to obtain specific measurements for the endogeneous as well as human transgene protein in a transgenic model
I want to obtain specific measurements for protein isoforms
Provides a seamless switch from TMT® based discovery into biomarker validation, without purchasing AQUA peptides, by combining isotopic TMT® peptide labelling with SRM. Suitable for the measurement of 5 - 50 candidate biomarkers in all sample types. Quantitation is relative to a defined, characterized universal reference. Learn More.
Proteome Sciences has extensive expertise in the development of classical SRM assays using heavy AQUA peptides for a wide range of applications. Where possible, peptide selection will be based on empirical data from our extensive database of proteomics discovery studies. Our expert team will guide you in the best assay method for your target proteins and the samples in which you want to routinely measure them in. Learn More.